Compare Novo Nordisk A/S (NVO) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs US Bancorp — how do they compare? Novo Nordisk A/S trades at $44.69 (market cap $200.69B), while US Bancorp trades at $62 (market cap $97.36B). The key difference: Novo Nordisk A/S is far larger — about 2.1× US Bancorp's market cap, and Novo Nordisk A/S pays the higher dividend (3.98%). Which is the better fit depends on your goals.
| NVO | USB | |
|---|---|---|
Market Cap | $200.69B | $97.36B |
Sector | Health | Financials |
52-Week High | $63.98 | $65.42 |
52-Week Low | $35.29 | $45.28 |
Enterprise Value | $215.49B | — |
Dividend Yield | 3.98% | 3.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $45.16, down 3.09% today, with bearish technical signals but strong fundamentals. The stock shows robust profitability with 35.35% net margin and 59.82% ROE, supported by consistent earnings beats. Recent developments include positive pediatric obesity trial results for semaglutide and Wegovy pill launch in Germany. Cash flow remains healthy with $10.81B net inflow in 2025, though 2026 projections show a decline.
NVO presents a mixed outlook with strong fundamental metrics offset by technical weakness and competitive pressures. Investment opportunity lies in the expanding GLP-1 market and pipeline developments, while risks include market share loss to Eli Lilly and failed cardiovascular drug trials. Analyst consensus leans bullish with 57.9% buy ratings, but recent prescription slowdown concerns warrant caution.
U.S. Bancorp (USB) trades at $62.49, down 1.39% today, with a bearish technical signal and neutral oscillators. The stock shows strong fundamentals with a P/E of 12.47 and net income margin of 27.61%, supported by three consecutive quarterly EPS beats. Recent news highlights innovation in digital payments and business banking expansion. Cash flow trends indicate volatility, with 2025 net cash flow negative at -$9.61 billion.
The outlook is mixed: analyst consensus targets $70.27 (12.4% upside) with 50% buy ratings, but technicals suggest near-term pressure. Key risks include debt levels and macroeconomic sensitivity. Earnings growth and dividend stability ($0.52 quarterly) provide support, though investor sentiment is cautious amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
